A Modular Platform: Bexson’s Wearable On-Body Delivery System

Co-developing with the Stevanato Group, Bexson introduces a platform providing users with control of their post-surgical pain management (BB106 ketamine) and delivery of other small molecules in a safe, intuitive, and stress-free experience.

Explore Military Applications →

The gold standard for mobile bio-availability.

A Completely Enhanced Route of Drug Delivery

We are meeting our ambitious goal to develop a modular device leapfrogging prior industry innovations for subcutaneous or dose metered infusion. 

Our wearable device is pre–filled and pre-sterilized with features that offer best-in-class tamper resistance and diversion control to mitigate potential misuse.

Potential Routes of Delivery

Bexson’s Device & SeVALENT™: The solution for pain management, mental health treatments and other small molecule delivery

Intravenous
Intramuscular
Oral
Intranasal
Sublingual
Dosing

Both steady state & bolus

Bolus only

Bolus only

Bolus only

Bolus only

Potential Tx Settings

In-clinic only

In-clinic only

In-clinic & at home

In-clinic & at home

In-clinic & at home

Bioavailability

Highest 100%

High 93%

Very Low
11-20%

Mod 25-50%

Low 30%

Metabolite Exposure

Low

Low

Very High

High

High

Procedural Burden

High

Moderate

Low

Low to Moderate

Low to Moderate

Response Variability

Low

Low

High

Moderate to High

Moderate to High

Dosing

Both steady state & bolus

Potential Tx Settings

In-clinic only

Bioavailability

Highest 100%

Metabolite Exposure

Low

Procedural Burden

High

Response Variability

Low

Dosing

Bolus only

Potential Tx Settings

In-clinic only

Bioavailability

High 93%

Metabolite Exposure

Low

Procedural Burden

Moderate

Response Variability

Low

Dosing

Both steady state & bolus

Potential Tx Settings

In-clinic & at home

Bioavailability

High > 80%

Metabolite Exposure

Low

Procedural Burden

Low to Moderate

Response Variability

Low

Dosing

Bolus only

Potential Tx Settings

In-clinic & at home

Bioavailability

Very Low 11-20%

Metabolite Exposure

Very High

Procedural Burden

Low

Response Variability

High

Dosing

Bolus only

Potential Tx Settings

In-clinic & at home

Bioavailability

Mod 25-50%

Metabolite Exposure

High

Procedural Burden

Low to Moderate

Response Variability

Moderate to High

Dosing

Bolus only

Potential Tx Settings

In-clinic & at home

Bioavailability

Low 30%

Metabolite Exposure

High

Procedural Burden

Low to Moderate

Response Variability

Moderate to High

Patient Activation
and Pause Button
Visual User Feedback
Bolus Button
Adhesive Patch

A Partnership to Break Ground

Bexson has partnered with the Stevanato Group, one of the world’s leading drug containment, drug delivery, and component development & manufacturing companies.

Read the Latest Article

USE CASE SCENARIO

A New Route of Drug Delivery


Infectious Endocarditis is a serious, life-threatening bacterial infection of heart tissue that is a common problem in intravenous (IV) drug delivery, due to the introduction of skin flora to the blood circulation. These patients usually need potent, long-term antibiotic treatments that can only be achieved through daily IV infusions – requiring hospitalization, daily clinic visits, and/or home health services.

The unique Bexson/Stevanato Group product line can resolve the need for IV delivery, increase safety and convenience, and vastly reduce the cost of care and procedural burden. Rather than an extended hospital stay or daily travel to the clinic, patients would be able to place the patch pump themselves and deliver the therapy at home without IV catheters, saline bags, and unwieldy poles and IV pumps.

If subcutaneous delivery is preferable to IV or oral administration, why aren’t more drugs delivered subcutaneously?

Many drugs would cause tissue irritation if delivered subcutaneously due to non compatible solution pH and osmolality. These factors can cause sterile abscess. In addition, large volumes also create issues with this route of administration. 

However, Bexson’s 7-Valence Salt formulation normalizes hundreds of drug APIs to a near exact match of the pH and osmolality of subcutaneous tissue and permits solution concentration (on average approximately 10:1) to allow wearable technology.

This remarkable advancement paired with the new delivery platform represent a massive opportunity to resolve the inconvenience and cost of the IV drug delivery market ($350 billion in size by 2030)

Innovations & Improvements

The two-part design allows the drive unit to be separated from the drug pod for reuse, while having the capacity to produce pre-filled and pre-sterilized drug pods. This is also a key feature of the tamper resistance and diversion control strategy because it forbids the possibility of running more than one pod at a time.

Award Winning Collaboration

The joint Bexson and Stevanato Group strategy has been to design an innovative device that can be repurposed effectively for many different applications. The device is highly modular and will accommodate many other small-molecule formulations. 

At the same time, Bexson Biomedical is tailoring SeVALENT™ formulations with therapeutic dosing potential ranging from 1-hour to 3-days using the standard and modular 3 mL cartridge. 

The companies’ respective technologies complement each other. Having a partner that can manage an entire project – from container closure system to assembly technology, up to mass production – is key to bringing a device to market faster and more easily.

Read Article

Military Applications

The combination of AKESO and BB106 is designed to provide non-opioid pain management on the battlefield.

Explore Military Applications